In 2025, the world of type 1 diabetes research didn’t just move forward—it leapt into a new era. On this episode of The Deep Dive, we explore the breakthroughs that are reshaping what it means to live with T1D. At the heart of this revolution is Vertex Pharmaceuticals and its remarkable stem cell–derived therapy, zimislecel. For the first time, clinical trial participants are achieving true insulin independence, leaving injections and pumps behind. Even the most dangerous lows—those sudden, life‑threatening drops in blood sugar—have nearly vanished. It’s a glimpse of a future where lab‑grown beta cells restore the body’s natural rhythm. But the story doesn’t stop there. Scientists are now refining gene‑editing and encapsulation technologies to protect these new cells from autoimmune attack. Imagine a treatment that works without  ...